These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34729104)

  • 1. A Prospective Cohort Study of Biomarkers in Squamous Cell Carcinoma of the Anal Canal (SCCAC) and their Influence on Treatment Outcomes.
    Moniz CMV; Riechelmann RP; Oliveira SCR; Bariani GM; Rivelli TG; Ortega C; Pereira AAL; Meireles SI; Franco R; Chen A; Bonadio RC; Nahas C; Sabbaga J; Coudry RA; Braghiroli MI; Hoff PM
    J Cancer; 2021; 12(23):7018-7025. PubMed ID: 34729104
    [No Abstract]   [Full Text] [Related]  

  • 2. Long term clinical outcomes and associated predictors of progression free survival in anal canal cancer.
    Ponce SEB; Erickson BA; Hall WA; Bedi M; Martens MJ; Siker M; Thomas J; George B; Ludwig K; Peterson C; Ridolfi T; Longo JM
    J Gastrointest Oncol; 2022 Feb; 13(1):185-196. PubMed ID: 35284138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort.
    Iseas S; Prost D; Bouchereau S; Golubicki M; Robbio J; Oviedo A; Coraglio M; Kujaruk M; Méndez G; Carballido M; Roca E; Gros L; De Parades V; Baba-Hamed N; Adam J; Abba MC; Raymond E
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of p53, HIF1a, Ki-67, CA-9, and GLUT1 Expression on Treatment Outcomes in Locally Advanced Cervical Cancer Patients Treated With Definitive Chemoradiation Therapy.
    Gaber G; El Achy S; Khedr GA; Parimi V; Helenowksi I; Donnelly ED; Strauss JB; Woloschak G; Wei JJ; Small W; Refaat T
    Am J Clin Oncol; 2021 Feb; 44(2):58-67. PubMed ID: 33284239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal.
    Lee G; Kim DW; Muralidhar V; Mitra D; Horick NK; Eyler CE; Hong TS; Drapek LC; Allen JN; Blaszkowsky LS; Giantonio B; Parikh AR; Ryan DP; Clark JW; Wo JY
    Oncologist; 2020 Dec; 25(12):1015-1022. PubMed ID: 32827337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53.
    Meulendijks D; Tomasoa NB; Dewit L; Smits PH; Bakker R; van Velthuysen ML; Rosenberg EH; Beijnen JH; Schellens JH; Cats A
    Br J Cancer; 2015 Apr; 112(8):1358-66. PubMed ID: 25871546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
    Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
    Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
    Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
    Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
    Zhu J; Wen H; Bi R; Wu Y; Wu X
    J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
    Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A
    Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis.
    Sher DJ; Schwartz DL; Nedzi L; Khan S; Hughes R; Fidler MJ; Koshy M
    Oral Oncol; 2016 Mar; 54():58-67. PubMed ID: 26794877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.
    Amini A; Jasem J; Jones BL; Robin TP; McDermott JD; Bhatia S; Raben D; Jimeno A; Bowles DW; Karam SD
    Oral Oncol; 2016 May; 56():1-7. PubMed ID: 27086480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.